Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04002947
Title Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

diffuse large B-cell lymphoma

Therapies

Acalabrutinib + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate

Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
National Institutes of Health Clinical Center Recruiting Bethesda Maryland 20892 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field